A genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence has been identified by scientists.
The study, advances the 2005 findings of the NCIC Clinical Trials Group study JBR.10, conducted in collaboration with the U.S. National Cancer Institute.
Bile Duct Cancer
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the liver or outside the liver.
Advertisement
The JBR.10 findings showed significant survival benefit from the anti-cancer drugs vinorelbine and cisplatin in patients with early-stage (stage I and II) non-small cell lung cancer whose tumors had been surgically removed.
Principal investigator Dr. Ming Tsao, pathologist at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN), and Professor of Laboratory Medicine and Pathobiology at the University of Toronto research team and collaborators at NCIC Clinical Trials Group at Queen's University performed a genetic analysis of tumor tissue from 133 of the 482 patients from the JBR.10 study who had banked frozen tumor samples.
![Anal Cancer]( "Anal Cancer")
Anal cancer is a rare tumor and constitutes 2 to 4% of all large intestine cancers. It can be either anal squamous cell cancer, Cloacogenic cancer, ano-rectal or anal adeno-carcinoma, or anal Melanoma
The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).
They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease experienced the greatest benefit from chemotherapy - with a 67 percent reduction in the risk of death - while chemotherapy did not reduce the risk of death in patients designated as low risk.
While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao's study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post-operative chemotherapy.
The study has been published online in the Journal of Clinical Oncology (JCO 64325).
Source: ANI
Anal Cancer
Anal cancer is a rare tumor and constitutes 2 to 4% of all large intestine cancers. It can be either anal squamous cell cancer, Cloacogenic cancer, ano-rectal or anal adeno-carcinoma, or anal Melanoma
Advertisement
The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).
They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease experienced the greatest benefit from chemotherapy - with a 67 percent reduction in the risk of death - while chemotherapy did not reduce the risk of death in patients designated as low risk.
While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao's study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post-operative chemotherapy.
The study has been published online in the Journal of Clinical Oncology (JCO 64325).
Source: ANI
Colo-rectal cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological therapy. Some people require a combination of treatments.
Advertisement
 Women and CancerCancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable